Skip to main content
. 2015 Apr 29;10(4):e0121715. doi: 10.1371/journal.pone.0121715

Table 2. Assessment of network meta-analysis study characteristics.

Journal quality (n = 301)* Date of study publication (n = 318) Source of study support (n = 315)**
Assessment criteria All studies (n = 318) Low impact factor (<3.534) (n = 147) High impact factor (≥3.534) (n = 154) p-value Older studies (published prior to 2013) (n = 167) Recent studies (2013, 2014) (n = 151) p-value Industry support (n = 98) Non-Industry support/ no support (n = 217) p-value
General study characteristics
Number of treatments compared 6.3 (±6.4) 6.8 (±8.5) 6.0 (±3.9) 0.3136 6.0 (±4.2) 6.7 (±8.2) 0.3816 5.9 (±3.6) 6.5 (±7.3) 0.446
Total number of studies 32.9 (±45.5) 28.3 (±38.6) 36.5 (±46.9) 0.0992 30.5 (±50.2) 35.5 (±50.2) 0.3341 22.7 (±29.4) 37.4 (±50.5) 0.0079
Total number of patients 26875 (±65936) 21938 (±46061) 33292 (±82859) 0.1549 23711 (±49899) 30460 (±80375) 0.3732 10945 (±13183) 33864 (±77635) 0.005
HTA region (UK, AUS and Canada) 110 (35%) 50 (34%) 56 (36%) 0.6709 68 (47%) 42 (28%) 0.0156 48 (49%) 62 (28%) 0.0003
Journal impact factor 5.5 (±6.2) NA NA NA 5.8 (±6.5) 5.2 (±5.9) 0.3791 3.1 (±1.7) 6.5 (±7.1) <0.0001
Study method
Bayesian framework 214 (67%) 91 (62%) 109 (71%) 0.1038 106 (63%) 108 (72%) 0.1273 75 (77%) 139 (63%) 0.0191
Risk of bias assessment of included studies 223 (70%) 100 (68%) 111 (72%) 0.4446 103 (62%) 120 (79%) 0.0005 53 (54%) 170 (77%) <0.0001
Adjustment for covariates 92 (29%) 35 (24%) 51 (33%) 0.0744 54 (32%) 38 (25%) 0.1601 37 (38%) 55 (25%) 0.0205
Random effects model*** 221 (70%) 98 (67%) 114 (75%) 0.1609 116 (69%) 106 (71%) 0.7453 67 (68%) 155 (71%) 0.6243
Assessment of model fit 127 (40%) 53 (36%) 70 (45%) 0.0979 69 (41%) 58 (38%) 0.5985 46 (47%) 81 (37%) 0.0894
Sensitivity analysis 179 (56%) 73 (50%) 96 (62%) 0.0267 88 (53%) 91 (60%) 0.1752 57 (58%) 122 (58%) 0.6542
Consistency of direct and indirect evidence reported**** (closed loop studies only, n = 167) 116 (69%) 39 (57%) 73 (79%) 0.0017 57 (66%) 59 (73%) 0.3606 16 (39%) 100 (79%) <0.0001
Study transparency and reproducibility
Search terms reported 254 (80%) 112 (76%) 129 (84%) 0.1007 129 (77%) 125 (83%) 0.2201 61 (62%) 193 (88%) <0.0001
Network diagram 194 (61%) 85 (58%) 101 (66%) 0.1671 103 (62%) 91 (60%) 0.7974 62 (63%) 132 (60%) 0.5829
Extracted data from contributing clinical studies 206 (65%) 87 (60%) 106 (69%) 0.0955 116 (69%) 91 (61%) 0.1011 58 (60%) 149 (68%) 0.1726
Table of key clinical study characteristics 286 (90%) 128 (87%) 141 (92%) 0.2084 145 (87%) 141 (93%) 0.0527 89 (91%) 197 (90%) 0.729
Model code (Bayesian framework only, n = 214) 35 (16%) 9 (6%) 24 (16%) 0.0085 24 (14%) 11 (7%) 0.0439 8 (8%) 27 (12%) 0.2811
Presentation of study findings
Full matrix of head-to-head comparisons 203 (64%) 84 (57%) 108 (70%) 0.0191 110 (66%) 93 (62%) 0.4294 44 (45%) 159 (73%) <0.0001
Reported probability of being best (Bayesian framework only, n = 214) 87 (41%) 32 (22%) 51 (33%) 0.0277 41 (25%) 46 (30%) 0.2389 25 (26%) 62 (28%) 0.623
Ranking of included treatments (Bayesian framework only, n = 214) 67 (31%) 26 (18%) 40 (26%) 0.0829 29 (17%) 39 (26%) 0.0664 11 (11%) 56 (26%) 0.0031

Regions in which submissions to HTA agencies generally require a NMA;

* 17 studies published in journals with no associated impact factor;

** 3 studies for which source of study support was unclear;

*** 77 studies reported both fixed and random effects models, 38 studies did not report models used;

**** Consistency only reported for studies with a closed loop